<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03234114</url>
  </required_header>
  <id_info>
    <org_study_id>007</org_study_id>
    <nct_id>NCT03234114</nct_id>
  </id_info>
  <brief_title>Optimal Antithrombotic Therapy for ACS Patients Concomitant AF Undergoing New Generation DES Implantation</brief_title>
  <official_title>Optimal Antithrombotic Therapy for Acute Coronary Syndrome Patients Concomitant Atrial Fibrillation Undergoing New Generation Drug Eluting Stent Implantation</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>The First Affiliated Hospital with Nanjing Medical University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>The First Affiliated Hospital with Nanjing Medical University</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      It is a prospective, multi-centered, pragmatic clinical trial (PCT) which will enroll 800
      acute coronary syndrome (ACS) patients concomitant non-valvular atrial fibrillation (NVAF)
      undergoing new generation drug eluting stent (DES) implantation in China. In the randomized
      control group, subjects will receive triple antithrombotic therapy (TT) including warfarin
      with targeted INR 2.0-2.5, clopidogrel 75 mg per day and aspirin 100 mg per day for 4 weeks
      or 6 months in a randomized way after percutaneous coronary intervention (PCI) with new
      generation DES. Then a dual antithrombotic therapy including warfarin (targeted INR 2.0-2.5)
      and clopidogrel 75 mg per day will be administrated till 12 months after PCI. In the cohort
      group, dabigatran 110 mg b.i.d plus ticargrelor 90 mg b.i.d or clopidogrel 75 mg q.d will be
      dosed for 12 months after PCI. The baseline characteristics of all patients and outcomes in 2
      groups including primary composite endpoints of all-cause death, non-fatal myocardial
      infarction, unplanned revascularization, ischemic stroke, major bleeding (BARC criteria ≥
      3a), and secondary endpoints including death, myocardial infarction, unplanned
      revascularization, stent thrombosis, stroke and bleeding (BARC criteria 1-5) will be
      collected and compared during hospitalization and in 4 weeks (± 7 days), 6 months (± 7 days)
      and 12 months (± 7 days) after inclusion for office visits and in 2 weeks (± 7 days), 2
      months (± 7 days) and 3 months (± 7 days) after inclusion for phone call visits.
    </textblock>
  </brief_summary>
  <overall_status>Not yet recruiting</overall_status>
  <start_date type="Anticipated">February 1, 2018</start_date>
  <completion_date type="Anticipated">December 31, 2020</completion_date>
  <primary_completion_date type="Anticipated">June 30, 2020</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>primary composite endpoints of all-cause death, non-fatal myocardial infarction, unplanned revascularization, ischemic stroke, major bleeding (BARC criteria ≥ 3a)</measure>
    <time_frame>from baseline to 12 months (± 7 days) after inclusion</time_frame>
    <description>including all-cause death, non-fatal myocardial infarction, unplanned revascularization, ischemic stroke, major bleeding (BARC criteria ≥ 3a)</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>secondary endpoints of death, myocardial infarction, unplanned revascularization, stent thrombosis, stroke and bleeding (BARC criteria 1-5)</measure>
    <time_frame>from baseline to 12 months (± 7 days) after inclusion</time_frame>
    <description>death(all-cause and cardiogenic), myocardial infarction (all and non-fatal), unplanned revascularization [(non-)target lesion revascularization), (non-)target vessel revascularization], stent thrombosis (definite, probable, possible), stroke (ischemic and hemorrhagic) and bleeding (BARC criteria 1-5)</description>
  </secondary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Anticipated">800</enrollment>
  <condition>Acute Coronary Syndrome (ACS)</condition>
  <condition>Non-valvular Atrial Fibrillation (NVAF)</condition>
  <arm_group>
    <arm_group_label>4 weeks TT</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Randomized control group; Triple antithrombotic therapy (warfarin with targeted INR 2.0-2.5, clopidogrel 75 mg per day and aspirin 100 mg per day) for 4 weeks then warfarin (targeted INR 2.0-2.5) plus clopidogrel 75 mg per day till 12 months after PCI</description>
  </arm_group>
  <arm_group>
    <arm_group_label>6 months TT</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Randomized control group; Triple antithrombotic therapy (warfarin with targeted INR 2.0-2.5, clopidogrel 75 mg per day and aspirin 100 mg per day) for 6 months then warfarin (targeted INR 2.0-2.5) plus clopidogrel 75 mg per day till 12 months after PCI</description>
  </arm_group>
  <arm_group>
    <arm_group_label>12 months DT</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>A prospective cohort group; Dual antithrombotic therapy (dabigatran 110 mg b.i.d. plus ticargrelor 90 mg b.i.d.or clopidogrel 75 mg qd) for 12 months after PCI</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Triple Antithrombotic therapy</intervention_name>
    <description>Triple Antithrombotic therapy including warfarin with targeted INR 2.0-2.5 (Shanghai Xinyi pharma co., LTD, China), aspirin 100 mg per day (Bayer, Germany) and clopidogrel 75 mg per day (Sanofi, France)</description>
    <arm_group_label>4 weeks TT</arm_group_label>
    <arm_group_label>6 months TT</arm_group_label>
    <other_name>TT</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Dual antithrombotc therapy</intervention_name>
    <description>dabigatran 110 mg b.i.d. plus ticargrelor 90 mg b.i.d. or clopidogrel 75 mg per day</description>
    <arm_group_label>12 months DT</arm_group_label>
    <other_name>DT</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  ≥ 18 year

          -  ACS patients concomitant non-valvular AF underwent PCI and new-generation DES
             implantation

          -  CHA2DS2-VASc score ≥ 2 and in need of OAC treatment

          -  In a low to moderate risk of bleeding (HAS-BLED score &lt; 3)

          -  Volunteer to participate and sign informed consent

          -  Approved by national regulatory authorities ethics committees at participating
             centers.

        Exclusion Criteria:

          -  Previous stenting within recent 1 year

          -  Implantation of other types of stent during this PCI

          -  DES implantation in the left main stem;

          -  Cardiogenic shock or Killip III-IV

          -  STEMI patients with malignant arrhythmias or underwent electrodefibrillation or
             cardiopulmonary resuscitation or with cardiac mechanical complications (heart rupture,
             ventricular septal perforation, nipple muscle fracture, etc.)

          -  History of severe gastrointestinal or intracranial hemorrhage; active bleeding, recent
             trauma or major surgery in the last month; suspected or diagnosed aortic dissection

          -  Known allergy or intolerance to the study medications: aspirin, clopidogrel,
             dabigatran, warfarin, and heparin

          -  Previous enrollment in other trials without achieving primary endpoint

          -  Planned major surgery within the next 12 months with the need to discontinue
             antiplatelet therapy

          -  Abnormal liver or kidney function (ALT &gt; 3 ULN; diagnosed hepatitis or liver
             cirrhosis; CrCl &lt; 30 ml/min)

          -  History of blood system disease or bleeding tendency; hemoglobin &lt; 100 g/L, platelet
             count &lt; 100 × 10^9 cells/L, or &gt; 600 × 10^9 cells/L

          -  Malignancies or other comorbid conditions with life expectancy less than 1 year

          -  Pregnant (present, suspected, or planned) or lactating woman
      </textblock>
    </criteria>
    <gender>All</gender>
    <gender_based>Yes</gender_based>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Chunjian Li, Dr, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>The First Affiliated Hospital with Nanjing Medical University</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Chunjian Li, Dr, PhD</last_name>
    <phone>+86-25-68136018</phone>
    <email>drcjli@hotmail.com</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Xiaoxuan Gong, MD</last_name>
    <phone>+86-18851727059</phone>
    <email>xiaoxuangong@sina.com</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>First Affiliated Hospital of Nanjing Medical University</name>
      <address>
        <city>Nanjing</city>
        <state>Jiangsu</state>
        <zip>210029</zip>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <verification_date>January 2018</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>July 25, 2017</study_first_submitted>
  <study_first_submitted_qc>July 26, 2017</study_first_submitted_qc>
  <study_first_posted type="Actual">July 31, 2017</study_first_posted>
  <last_update_submitted>January 24, 2018</last_update_submitted>
  <last_update_submitted_qc>January 24, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">January 26, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>The First Affiliated Hospital with Nanjing Medical University</investigator_affiliation>
    <investigator_full_name>Chunjian Li</investigator_full_name>
    <investigator_title>Dr., MD, Ph.D, Director of CCU Ward</investigator_title>
  </responsible_party>
  <keyword>new generation drug eluting stent (DES)</keyword>
  <keyword>triple antithrombotic therapy (TT)</keyword>
  <keyword>pragmatic clinical trial (PCT)</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Syndrome</mesh_term>
    <mesh_term>Atrial Fibrillation</mesh_term>
    <mesh_term>Acute Coronary Syndrome</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Aspirin</mesh_term>
    <mesh_term>Ticlopidine</mesh_term>
    <mesh_term>Clopidogrel</mesh_term>
    <mesh_term>Warfarin</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>Undecided</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

